General Information of Drug (ID: DMD26XN)

Drug Name
Banyu Compound-24 Drug Info
Synonyms C-24
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10296561
TTD Drug ID
DMD26XN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug(s) Targeting Nociceptin receptor (OPRL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [3]
SER-100 DMDW5ZC Heart failure BD10-BD13 Phase 2 [4]
BTRX-246040 DMA9238 Major depressive disorder 6A70.3 Phase 2 [5]
LY-2940094 DMB5L6Q Major depressive disorder 6A70.3 Phase 2 [6]
NOCICEPTIN DMUPA7C Headache 8A80-8A84 Phase 1 [7]
JTC-801 DMV3UN4 Pain MG30-MG3Z Discontinued in Phase 2 [8]
ND1251 DMMLESX Depression 6A70-6A7Z Discontinued in Phase 1 [9]
ATI-17000 DMZJVR5 Irritable bowel syndrome DD91.0 Preclinical [10]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB Discovery agent N.A. Investigative [11]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nociceptin receptor (OPRL1) TTNT7K8 OPRX_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7361).
2 Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol. 2009 Jul 1;614(1-3):50-7.
3 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
4 Clinical pipeline report, company report or official report of Serodus ASA.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.
7 Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.
8 Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23(2):301-3.
9 The nociceptin receptor as a potential target in drug design. Drug News Perspect. 2001 Aug;14(6):335-45.
10 Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.
11 Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.